Pharmatech AI ($PCH) Presale

Pharmatech AI presale — An Introduction

Welcome. This article is about Pharmatech AI and its presale. If you are curious about crypto, medicine, or new projects, you will find this useful. We will talk about what Pharmatech AI is, how it can help crypto and pharma, its special features, its roadmap, its whitepaper, its tokenomics, its team and how much it has raised so far, and how to join the presale. 

Pharmatech AI

Pharmatech AI is a new project that mixes artificial intelligence (AI) with pharmaceutical research (making new medicines). The official website is. The goal is to speed up how new drugs are discovered, especially for pain relief, cannabinoids (plant compounds), and other medical fields. In simpler terms: Pharmatech AI wants to let science and computers work together. Instead of doing many slow lab experiments, the AI will simulate and predict which molecules and drug combinations might work. This can save time, money, and errors. The project also issues a crypto token (often “PCH” in their materials) which is part of its ecosystem. People buying during the presale (early stage of token sales) can get tokens before they appear on exchanges. The “presale” is often cheaper or with bonus terms compared to public sale.

How Pharmatech AI will benefit the crypto space

Pharmatech AI brings some new uses of blockchain and tokens into the pharma world. Here are a few ways it can benefit the crypto space:

1. Real-world value in health / drugs: Many crypto projects are “just finance” or “just tokens.” But Pharmatech AI ties its token to real science, real patents, and real revenue from drug licensing.

2. Profit sharing & staking: The project plans to share part of its revenue with token holders via staking (locking tokens). That means holders can get stablecoin or other rewards.

3. Governance & participation: Token holders might vote on scientific priorities, licensing decisions, or research directions. This gives the crypto community a role in the real science.

4. Deflationary mechanics: Pharmatech AI describes a “buy-back and burn” mechanism. That means when revenue comes in, some tokens are bought from the market and destroyed (burned).

5. Bridging sectors: It helps bring together biotech, pharma, and crypto. That opens the door for more pharma + blockchain projects, more investment, and more interest in tokenizing real innovation.

Pharmatech AI Features

Here are the special features that Pharmatech AI claims. These set it apart from many other crypto or biotech projects.

• AI-MDIP (Multi-Drug Interaction Predictor): This is their core AI model. It predicts how different drugs (or molecules) interact with each other, and whether their combination is safe or effective.

• Proprietary data & labs: Pharmatech AI says it has its own research center, labs, and data generation to feed its AI models.

• Revenue sharing / staking: Token holders can stake PCH and receive 70% of the platform’s profits paid in stablecoins (quarterly).

• Buy-back & burn mechanism: Part of revenue is used to buy tokens and burn them, lowering supply to support long-term value.

• License auctions & marketplace: The platform plans to auction drug licenses or let partners bid for rights using tokens.

• Fixed supply: The token supply is capped (1 billion PCH).

• Token usage inside ecosystem: The token is used for governance, staking, licensing auctions, community incentives, etc.

Pharmatech AI presale details

Below are the details known so far about the Pharmatech AI presale / token sale. Always confirm these on their official site or whitepaper before participating.

• Presale status: The presale is active (LIVE).

• Token name & ticker: PCH (Pharmatech AI token).

• Total token supply: 1,000,000,000 (1 billion PCH).

• Presale rounds / price stages:
    • Pre-Seed: price ~ $0.00400 per PCH
    • Seed round: ~ $0.00475
    • KOL round: ~ $0.00725
    • Public round: ~ $0.00975

• Fundraising goal / total raised so far: They show that total value raised across rounds is about $2,602,500.

• Token unlock / vesting: Team and advisors have cliffs and linear release; early rounds partial unlock at TGE then vest.

• Listing / launch price: $0.00975 per PCH for the public sale / listing.

• Initial Market Cap: Initial MC (IMC): ~$494,800; Fully diluted MC (FDMC): ~$9.75 million.

• Acceptable currencies / platforms: They use a BEP-20 token (on Binance Smart Chain), likely accepting BNB or stablecoins.
  How to participate / buy tokens (step-by-step):

1. Visit, go to presale/register page.

2. Join whitelist by submitting address, KYC, or email, as required.

3. Connect your crypto wallet (e.g. MetaMask, Trust Wallet) to the presale app.

4. Send the allowed token (BNB or stablecoin) to the presale contract.

5. Receive PCH tokens in your wallet (after token generation event, TGE).

6. After listing, you may trade or stake.

Pharmatech AI Roadmap

The roadmap gives a timeline of how Pharmatech AI plans to develop. Based on their published materials, here is what they plan:

• Short term / Phase 1: Launch the presale; build out core AI model; set up lab and data pipelines.

• Mid term / Phase 2: Complete proof-of-concept drug candidates; begin licensing and partnerships; launch staking & revenue sharing; start buy-backs & burns.

• Long term / Phase 3: Scale up AI model; expand into more disease areas; list on multiple exchanges; grow user base, token ecosystem, and revenue streams. They also show a physical campus, 120k m² or more lab research center, as part of infrastructure.

Pharmatech AI Whitepaper

The whitepaper is the blueprint document. Based on what is publicly advertised:

• It describes how AI, graph neural networks, cheminformatics, molecular modeling, and simulation are integrated into AI-MDIP.

• It highlights the global drug discovery market, pain relief market, cannabinoid therapies, and nanomedicine as areas of high growth.

• It lays out roles for PCH tokens: staking, governance, licensing, community incentives, auctions.

• It details revenue models: pharma licenses, subscriptions, data marketplace, platform services.

• It gives vesting, token release schedules, and governance mechanisms.

Pharmatech AI Tokenomics

Tokenomics describes how the token is created, distributed, and how scarcity, utility, and incentives are aligned.

• Total fixed supply: 1,000,000,000 PCH (no inflation).

• Allocation / distribution: Presale/public rounds, team, advisors, treasury, liquidity.

• Vesting & release schedule: Team 12-month cliff then 36 months; advisors 6-month cliff then 12 months linear; early rounds partial unlock at TGE, rest over 12 months.

• Token utility: Governance voting, staking to earn profit share (70% revenue share), using tokens to bid/purchase licensing rights, incentives for community engagement.

• Deflationary mechanism: Buy-backs and token burns using revenue generated.

• Market caps & valuations: Initial MC ~$494,800; FDMC ~$9.75 million.

• Revenue share mechanics: Stakers receive 70% of profits, likely in stablecoins, on a quarterly basis.

Pharmatech AI team details

Information on the full team is sparse in public sources. The entity is registered as PHARMATECH AI LTD in the UK under company number 16569900. The official site does not list names and backgrounds of all founders or scientific leads. Since team verification is critical, you should request full resumes, LinkedIn profiles, past projects, publications, or advisory boards from the project directly before investing.

Pharmatech AI fundraised

So far, Pharmatech AI shows the following fundraising data:

• Pre-Seed: about $280,000 at $0.00400 per token

• Seed: about $498,750 at $0.00475

• KOL Round: about $507,500 at $0.00725

• Public Round: about $1,316,250 at $0.00975

• Total raised: ~$2,602,500 across all rounds

Conclusion & Disclaimer

Conclusion: Pharmatech AI is a bold attempt to bring together artificial intelligence, pharmaceuticals, and crypto. Its presale offers early access to a token tied to real scientific research, drug licensing, and revenue sharing. Its features—AI model, staking rewards, buy-backs, governance, lab infrastructure—make it interesting for those who want more than a speculative token. The roadmap is ambitious, and the tokenomics are detailed and designed for long-term alignment.
If Pharmatech AI can deliver real drug candidates, license deals, and revenue, then the token may gain real value. But that is a high barrier: biotech is risky, and regulatory/clinical success is never guaranteed.